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Abstract
Introduction: End-stage renal disease (ESRD) is a major public health problem. Although kidney transplantation is
a viable therapeutic option, this therapy is associated with significant limitations, including a shortage of donor
organs. Induced pluripotent stem (iPS) cell technology, which allows derivation of patient-specific pluripotent stem
cells, could provide a possible alternative modality for kidney replacement therapy for patients with ESRD.
Methods: The feasibility of iPS cell generation from patients with a history of ESRD was investigated using lentiviral
vectors expressing pluripotency-associated factors.
Results: In the present article we report, for the first time, generation of iPS cells from kidney transplant recipients
with a history of autosomal-dominant polycystic kidney disease (ADPKD), systemic lupus erythematosus, or Wilms
tumor and ESRD. Lentiviral transduction of OCT4, SOX2, KLF4 and c-MYC, under feeder-free conditions, resulted in
reprogramming of skin-derived keratinocytes. Keratinocyte-derived iPS cells exhibited properties of human
embryonic stem cells, including morphology, growth properties, expression of pluripotency genes and surface
markers, spontaneous differentiation and teratoma formation. All iPS cell clones from the ADPKD patient retained
the conserved W3842X mutation in exon 41 of the PKD1 gene.
Conclusions: Our results demonstrate successful iPS cell generation from patients with a history of ESRD, PKD1
gene mutation, or chronic immunosuppression. iPS cells from autosomal kidney diseases, such as ADPKD, would
provide unique opportunities to study patient-specific disease pathogenesis in vitro.
Introduction
The prevalence of chronic kidney disease and end-stage
renal disease (ESRD) is increasing worldwide [1]. Simul-
taneously, the total Medicare cost of ESRD has risen
from $12.2 billion in 2000 to $39.5 billion in 2010 [1].
ESRD is incurable, requiring hemodialysis or preferably
renal transplantation. These therapies are associated
with considerable limitations, however, including the
shortage of available donor organs and a lifelong immu-
nosuppressive regimen [2]. Moreover, despite significant
improvement in 1-year kidney allograft survival, the rate
of chronic graft loss after the first year remains substan-
tial [3].
The most common causes of ESRD in the United
States are diabetes and hypertension [4], while the inci-
dence of nondiabetic ESRD, such as glomerular diseases
and cystic diseases, are increasing. Autosomal-dominant
polycystic kidney disease (ADPKD) is the most common
life-threatening, lethal genetic disease, affecting approxi-
mately 7 million people worldwide. Mutations in the
PKD1 and PKD2 genes are responsible for ADPKD in
85% and 15% of patients, respectively. ADPKD is the
leading hereditary cause of ESRD, accounting for
approximately 4% of ESRD [5]. Wilms tumor (WT) or
nephroblastoma is a rare kidney cancer, and is responsi-
ble for 95% of all kidney tumors in children [6].
* Correspondence: ikeda.yasuhiro@mayo.edu
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN55905, USA
Full list of author information is available at the end of the article
Thatava et al. Stem Cell Research & Therapy 2011, 2:48
http://stemcellres.com/content/2/6/48
© 2011 Thatava et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Although the risk of ESRD is low for the majority of
WT patients, ESRD can occur from chemotherapy-
induced nephrotoxicity or radiation-induced obstructive
uropathy. Those with WT-aniridia syndrome or asso-
ciated genitourinary anomalies (hypospadias or cryptor-
chism) are at higher risk of ESRD, and therefore require
indefinite screening for renal function [7]. Systemic
lupus erythematosus (SLE) is an autoimmune disease
with inflammation-mediated multiorgan damage. Kidney
is one of the main target organs in SLE, and lupus
nephritis is a major cause of morbidity and mortality.
Approximately 10% of patients with SLE develop ESRD
[8]. In SLE patients with kidney transplant, recurrence
of the disease in the graft is frequently observed [9].
Stem cell-based regenerative medicine approaches hold
great promise to treat patients with degenerative diseases.
Successful replacement, or augmentation, of the function
of damaged renal cells by stem cells would provide a
novel cell-based therapy for renal diseases. Although
adult stem cells, such as bone marrow stem cells, can dif-
ferentiate into renal resident cells and participate in kid-
ney regeneration [10], their engraftment into injured
tubules and development into functional renal tissues are
not sufficient to repair acute renal injury [11,12]. Accord-
ingly, pluripotent stem cell-based kidney tissue engineer-
ing has attracted considerable attention. Although
embryonic stem (ES) cells have provided a unique plat-
form for pluripotent stem cell-based regenerative medi-
cine applications, their widespread use in the clinic is
restricted by ethical issues and allogenic mismatch.
Generation of induced pluripotent stem (iPS) cells
from adult somatic cells from mouse fibroblasts was
first reported through retroviral transduction of Oct4,
Sox2, Klf4 and c-Myc genes [13]. Subsequently, human
iPS cells were generated from human fibroblasts
through introduction of a set of stemness factors:
OCT4, SOX2, KLF4 and c-MYC [14,15], or OCT4,
SOX2, NANOG and LIN28 [16]. Since iPS cells resem-
ble ES cells in their ability to generate cells of three
germ layers, patient-specific iPS cells offer potential
solutions for the ethical and histo-incompatibility issues
of ES cells. Moreover, disease-specific iPS cell derivation
and differentiation into relevant tissues/organs could
provide unique opportunities to model disease progres-
sion in vitro, to screen patient-specific drugs and, ulti-
mately, to enable immunosuppression-free cell
replacement therapy. Although autologous iPS cells have
been generated from patients with various diseases/dis-
orders [17-23], the feasibility and reproducibility of iPS
cell derivation from kidney diseases, such as ADPKD,
has remained elusive.
In the present study, we recruited patients who had a
clinical history of ESRD due to ADPKD, SLE or WT/
obstructive uropathy, kidney transplant and maintenance
on an immunosuppressive regimen, and examined the fea-
sibility of iPS cell derivation. We were able to reprogram
skin-derived keratinocytes into patient-specific iPS cells.
These kidney disease-specific iPS cell clones expressed
pluripotency markers and differentiated into cells of three
germ layers in vitro and in vivo, verifying their pluripo-
tency. Our results therefore demonstrated successful iPS
cell generation from patients with a history of ESRD,
PKD1 gene mutation or chronic immunosuppression. iPS
cells from autosomal kidney diseases, such as ADPKD,
would enable studies of patient-specific renal disease
pathogenesis at a cellular level, while autologous iPS cells
could be used for novel kidney replacement therapy.
Materials and methods
All studies were approved by the Mayo Institutional
Review Board and Institutional Animal Care and Use
Committee. We recruited patients from the kidney
transplant program. All patients provided written
informed consent for this research study. Patient infor-
mation is summarized in Table 1.
Derivation of patients’ fibroblasts and keratinocytes
under xeno-free conditions
Skin biopsy of an 8 mm punch was obtained and pro-
cessed to derive dermal keratinocytes and fibroblasts;
briefly, tissue was submerged in enough dispase solution
(Invitrogen catalog number 17105-041; Invitrogen,
Grand Island, NY, USA) for either 16 to 21 hours at 4°C
or 3 to 4 hours at 37°C for separation of epidermis from
dermis. Once separated, epidermis was collected into a
vial containing recombinant trypsin/ethylenediamine tet-
raacetic acid (catalog number R-009-50; Invitrogen) for
separation of fibroblasts and keratinocytes, and incubated
at 37°C for 15 to 30 minutes. Defined trypsin inhibitor
(catalog number R-007-100; Invitrogen) was used to neu-
tralize the trypsin/ethylenediamine tetraacetic acid.
Human keratinocytes and fibroblasts were cultured in an
animal-origin-free media. EpiLife Medium (catalog num-
ber M-EPI-500-CA; Invitrogen) with Supplement S7 (cat-
alog number S-017-5; Invitrogen) was used for human
keratinocytes, while fibroblast medium (FM-acf, catalog
number 2321; Sciencell Research Laboratories, Carlsbad,
CA, USA) was used for fibroblasts. Dermal fibroblasts
and keratinocytes were cultured on collagen-coated flasks
(coating matrix, catalog number R-011-K; Invitrogen)
and were plated for reprogramming or frozen using
Synth-a-Freeze (catalog number R-005-50; Invitrogen).
Generation of patient-derived iPS cells under feeder-free
conditions
Dermal keratinocytes were reprogrammed to generate
human iPS cell clones as described previously, with
minor modifications [24,25]. Briefly, 20% confluent
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SOX2-expressing, KLF4-expressing and c-MYC-expres-
sing lentiviral vectors each at a multiplicity of infection
of 5 in EpiLife medium. After overnight viral infection,
cells were fed with fresh complete EpiLife medium. Cul-
ture supernatants were replaced daily with EpiLife med-
ium until 4 days after vector infection. At day 5, the
medium was replaced with a feeder-free iPS cell med-
ium, which contained HEScGRO (catalog number
SCM020; Millipore, Billerica, MA, USA) with 25%
mTeSR1 medium (catalog number 05850; Stem Cell
Technologies, Vancouver, BC, Canada) and antibiotics,
but no additional basic fibroblast growth factor. Cells
were fed with fresh HEScGRO-based iPS cell medium
every 2 days. Putative iPS cell colonies were observed
within 2 weeks after viral vector transduction and pro-
pagated on matrigel-coated plates, as described pre-
viously [25]. Human keratinocytes were also infected
with lentiviral vectors expressing the three factors
OCT4, SOX2 and KLF4, without c-MYC, for possible c-
MYC-free reprogramming.
Immunocytochemistry and alkaline phosphatase staining
Undifferentiated patient-specific iPS cell clones were
fixed for 20 minutes at room temperature in 4% parafor-
maldehyde in PBS and then permeabilized with Triton
X-100 for 30 minutes. After 30 minutes of blocking
with 5% fetal bovine serum in PBS with 0.1% Tween-20,
cells were stained with primary antibodies overnight at
4°C and, after PBS wash, incubated with secondary anti-
bodies (1 hour at room temperature at a dilution of
1:200). Nuclei were counterstained with 4,6-diamidino-
2-phenylindole (1:500; Sigma, St. Louis, MO, USA). Pri-
mary and secondary antibodies used for characterization
of iPS cells are listed in Supplementary Table S1 in
Additional file 1. After staining, cells were analyzed
using confocal laser-scanning microscopy (LSM 510
confocal scanning laser system; Zeiss, Thornwood, NY,
USA). For detection of alkaline phosphatase activity, the
alkaline phosphatase detection kit (Millipore, Billerica,
MA, USA) was used. Briefly, human iPS cells in culture
for 5 days were fixed with 4% paraformaldehyde for 2
minutes at room temperature. The cells were rinsed
with TBST buffer (20 mM Tris-HCl, pH 7.4, 0.15 NaCl,
0.05% Tween-20) and stained with naphthol/fast red
violet solution (mixture of fast red violet, naphthol AS-
BI phosphate solution and water in a 2:1:1 ratio) for 15
minutes in the dark. Cells were rinsed with TBST and
covered with PBS; alkaline phosphatase-positive cells
were imaged using a light microscope.
RNA isolation and RT-PCR analysis
Spontaneous differentiation
iPS cell clones were dissociated using collagenase type
IV (catalog number 07909; Stem Cell Technologies) and
then suspended cell clumps were cultured in basal
HEScGRO medium (SCM 021) in low-adhesion plates.
Embryoid bodies were formed in suspension, initially
cultured for approximately 7 to 14 days, and then trans-
ferred to knockout DMEM with 20% fetal bovine serum,
differentiated as a monolayer for another 10 to 14 days.
For evaluation of the presence of cells of three germ
layers, differentiated cells were fixed and stained with
the antibodies for immunofluorescence analysis. Primary
antibodies and secondary antibodies are listed in Supple-
mentary Table S1 in Additional file 1.
Teratoma formation and analysis
Undifferentiated WT, SLE and ADPKD iPS cell clones
were manually detached by collagenase type IV treat-
ment and injected subcutaneously into each flank of 8-
week-old to 10-week-old SCID-Beige mice. Tumors
were observed 4 to 6 weeks after injection, and collected
3 to 5 months after injection. Tumor samples were pro-
cessed by 10 μm cryosectioning, and stained H & E tis-
sue sections were analyzed.
DNA isolation and sequencing
Total DNA was isolated from ADPKD-iPS cells using
PureLink™ Genomic DNA kits (catalog number 25-
1012; Invitrogen). The ADPKD patient was previously
mutation characterized (family 300004) [26]. To charac-
terize the W3842X mutation in the iPS cells, exon 41
was amplified with flanking primers and conventionally
sequenced as previously described [26].
Results
Isolation and culture of patient-specific fibroblasts,
keratinocytes and generation of iPS cells
The patients with a history of renal diseases including
ADPKD, WT and SLE were from different age groups,
Table 1 Patient information
Patient Immunosuppressants Daily dose (mg) Length of exposure (years)
WT Mycophenolate/prednisone/tacrolimus 3.5/10/1,000 4
SLE Mycophenolate/prednisone/tacrolimus 3/7/1,000 11
ADPKD Mycophenolate/tacrolimus 3.5/2,000 1
ADPKD, autosomal-dominant polycystic kidney disease; SLE, system lupus erythematosus; WT, Wilms tumor.
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(mycophenolate, prednisone a n dt a c r o l i m u s )( T a b l e1 ) .
Skin biopsies obtained from patients were processed
under animal-component-free conditions and keratino-
cytes and fibroblasts were cultured in serum-free med-
ium. Undifferentiated keratinocytes could be expanded
over 10 passages, whereas fibroblasts stopped propaga-
tion after a few passages, most probably due to cellular
senescence. We therefore used keratinocytes for repro-
gramming. Keratinocytes were transduced with lentiviral
vectors expressing four pluripotency factors OCT4,
SOX2, KLF4 and c-MYC each at a multiplicity of infec-
tion of 5. Approximately five to 20 iPS cell-like colonies
formed in 10
5 infected cells. No iPS cell-like colonies
were formed in cells transduced with three factors with-
out c-MYC. iPS cell-like colonies were handpicked,
based on morphological criteria such as compact colo-
nies, high nucleus-to-cytoplasm ratios and prominent
nucleoli, and were expanded on Matrigel-coated plates
under feeder-free conditions. We identified patient-spe-
cific iPS cells derived from the WT patient as WT-iPS
cells, those derived from the SLE patient as SLE-iPS
cells and those derived from the ADPKD patient as
ADPKD-iPS cells.
Expression of pluripotency markers in patient-specific iPS
cell clones
Putative patient-specific iPS cell clones cultured under
feeder-free and serum-free conditions exhibited mor-
phology similar to that of human ES cells, characterized
by large nuclei and scant cytoplasm, with distinct bor-
ders (Figure 1A). All of the patient-specific iPS cell
clones were positive for alkaline phosphatase (Figure
1A). WT-iPS, SLE-iPS and ADPKD-iPS cell clones were
verified for the presence of cell surface markers SSEA-4,
TRA-1-60 and TRA-1-81 (Figure 1B). Similar to human
ES cells, these clones were negative for SSEA-1 expres-
sion. WT-iPS, SLE-iPS and ADPKD-iPS cell clones also
expressed pluripotency genes OCT4, SOX2, KLF4 and
NANOG by immunofluorescence (Figure 2A). In con-
trast, isotype control staining showed no notable signals
(Supplementary Figure S1 in Additional file 2). RT-PCR
analyses of total cellular RNA further confirmed expres-
sion of pluripotency-associated genes, including OCT3/
4, SOX2, GDF3, telomerase (TERT), KLF4, c-MYC and
NANOG in the WT-iPS, SLE-iPS and ADPKD-iPS cell
clones (Figure 2B). We then assessed whether expres-
sion of the vector transgenes was silenced in derived iPS
cell clones. RT-PCR analysis was performed to detect
OCT4-transgene-specific, KLF4-transgene-specific and
c-MYC-transgene-specific transcripts. The presence of
exogenous pluripotency genes was evident in most of
the clones. One of the ADPKD-iPS cell clones exhibited
silencing of exogenous genes (Figure 2C). Morphology
and expression of pluripotent genes indicated the estab-
lishment of patient-specific iPS cell clones from
keratinocytes.
Pluripotency validated through spontaneous
differentiation and teratoma formation
WT-iPS, SLE-iPS and ADPKD-iPS cell clones were
allowed to spontaneously differentiate in vitro,t h r o u g h
embryoid body cultures, and were assayed for the ability
to differentiate into cells of the three embryonic germ
layers. After 8 to 10 days culturing in suspension,
embryoid bodies were plated on chamber slides and
further cultured for 10 to 12 days. Immunostaining of
differentiated cells with markers of three germ layers
confirmed the presence of ectoderm (b-III-tubulin),
endoderm (FOXA2) and mesoderm (CD31) cells (Figure
3). To determine the pluripotency of derived iPS cell
clones in vivo, WT-iPS, SLE-iPS and ADPKD-iPS cells
were injected subcutaneously into immunodeficient
SCID-Beige mice and monitored for teratoma formation.
iPS cell lines produced tumors 3 to 5 months post injec-
tion (Figure 4). Histological examination confirmed
these tumors were teratomas with tissues of all three
germ layers, including neuronal-rosette-like cells, gut
tube-like structures, intestinal epithelial cells, adipose-
like tissues and muscle-like structures (Figure 4). These
results demonstrated that the renal disease-specific iPS
cells possess hallmark properties of pluripotent stem
cells.
Autosomal mutation in the PKD1 gene verified in ADPKD-
specific iPS cell clones
Our previous study has identified the heterozygous
W3842X mutation in the PKD1 gene in the ADPKD
patient (family 300004). We therefore tested whether
ADPKD-iPS cell clones from this patient retained het-
erozygous W3842X mutation. As shown in Figure 5,
sequence analysis of the PKD1 gene in the ADPKD-iPS
and WT-iPS cell clones confirmed the heterozygous
W3842X mutation only in the ADPKD-iPS cell clone,
demonstrating that cellular reprogramming did not
affect the autosomal mutation in the PKD1 gene.
Discussion
Autologous, patient-specific iPS cells could attain custo-
mized tissue engineering and immunosuppression-free
cell therapy for various diseases. For clinical applica-
tions, it is critical to derive iPS cells under a US Food
and Drug Administration-compliant process. Although
efficient and rapid generation of iPS cells from juvenile
human primary keratinocytes was demonstrated through
transduction with OCT4, SOX2, KLF4 and c-MYC [27],
the feasibility and reproducibility of patient-specific iPS
cell derivation from dermal keratinocytes required
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induced pluripotent stem (iPS) cell clones were generated from keratinocytes of Wilms tumor (WT), systemic lupus erythematosus (SLE) and
autosomal-dominant polycystic kidney disease (ADPKD) patients by ectopic expression of lentiviral vectors expressing OCT3/4, SOX2, KLF4 and c-
MYC. iPS cell clones from keratinocytes of the WT patient were termed WT-iPS, similarly for SLE-iPS and ADPKD-iPS. Two clones each were
analyzed for human embryonic stem (ES) characteristics (WT#5J, WT#20G, SLE#100H, SLE#20J, ADPKD#50B and ADPKD#10D). WT-iPS, SLE-iPS and
ADPKD-iPS clones were generated and maintained under feeder-free conditions, exhibiting morphology similar to human ES cells. (A) All of the
iPS cell clones expressed alkaline phosphatase (AP). (B) WT-iPS, SLE-iPS and ADPKD iPS clones expressed cell surface markers SSEA4, TRA-1-60
and TRA-1-81, whereas no notable staining was observed for SSEA1. The nucleus was revealed by counterstaining with 4,6-diamidino-2-
phenylindole. Phase-contrast images and AP images are 10× magnification. Immunofluorescence images were obtained at 40× magnification.
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Page 5 of 11Figure 2 Patient-specific induced pluripotent stem cell clones were analyzed for pluripotency-associated gene expression. (A) Wilms
tumor (WT)-induced pluripotent stem (iPS) cell, systemic lupus erythematosus (SLE)-iPS cell and autosomal-dominant polycystic kidney disease
(ADPKD)-iPS cell clone expression of stemness-associated genes was analyzed by immunofluorescence and RT-PCR analysis. WT-iPS, SLE-iPS and
ADPKD-iPS clones expressed high levels of OCT4, SOX2, KLF4 and NANOG. Immunofluorescence images were obtained at 40× magnification. (B)
Total cellular RNA from WT-iPS, SLE-iPS and ADPKD-iPS clones was isolated and analyzed for endogenous pluripotency genes by RT-PCR. WT-iPS,
SLE-iPS and ADPKD-iPS clones expressed gene transcripts of OCT4, SOX2, KLF4, NANOG, GDF3, hTERT and c-MYC. (C) For detection of silencing
of exogenous pluripotency genes, BJ fibroblasts were infected with lentiviral vectors expressing OCT4, SOX2, KLF4 and c-MYC. Three days after
viral vector transduction, RNA was isolated from infected fibroblasts, control uninfected fibroblasts, and WT-iPS, SLE-iPS and ADPKD-iPS clones.
RT-PCR was performed for transgenes KLF4, c-MYC and OCT4. GAPDH gene transcript was amplified as an internal RNA control. No template
(water) samples were included as controls.
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generation of kidney disease-specific iPS cells from skin
keratinocytes. Importantly, skin biopsies were processed
and expanded in animal-component-free reagents, and
keratinocytes were reprogrammed under feeder-free
conditions and expanded in serum-free media. Except
for Matrigel, which is derived from a mouse cell line
a n du s e dt oc o a tc u l t u r ep l a t e sf o ri P Sc e l lc u l t u r e ,n o
animal component-containing reagent was used for iPS
cell culture. Recently, fully defined adherent culture sub-
strates composed of synthetic or recombinant molecules
were found to support efficient human ES cell and iPS
cell expansion [28-30]. A combination of feeder-free
reprogramming of skin keratinocytes and one of these
defined coating substrates would thus allow Good man-
ufacturing practice-compliant iPS cell derivation, which
represents an important step towards clinical iPS cell
applications.
Important factors that may influence propagation of
skin-derived cells and their nuclear reprogramming are:
patient-specific cell survival defects; variations in age,
gender and ethnic backgrounds; and chronic use of var-
ious medications. In this study, we reprogrammed skin-
derived keratinocytes from patients with kidney trans-
plantation on immunosuppressants, including mycophe-
nolate, prednisone and tacrolimus. We were successful
in propagating keratinocytes and in generating iPS cells
from all three patients, demonstrating that age, disease
backgrounds including ADPKD, SLE and WT, and
chronic use of immunosuppressive drugs (especially
antiproliferative mycophenolate) have no effect on skin
cell propagation and iPS cell generation. Moreover, cel-
lular reprogramming efficiency was comparable between
keratinocytes from patients with ESRD and keratino-
cytes from healthy donors (data not shown). Our results
thus indicate the feasibility of iPS cell derivation from
patients with history of ESRD or maintained on chronic
immunosuppression. Interestingly however, expansion of
fibroblasts from skin biopsy samples collected from
these patients was problematic. Active cell division
stopped after few passages, most probably due to senes-
cence. Therefore, we cannot rule out the possibility that
long-term mycophenolate treatment might impair the
capacity of fibroblast propagation in vitro. Further study
will answer the potential impact of immunosuppressive
drugs on the growth of skin-derived fibroblasts. In this
regard, keratinocytes appeared to be a promising
somatic cell source for patient-specific iPS cell deriva-
tion, particularly when patients have been treated with
immunosuppressive drugs.
Integration of retroviral and lentiviral vectors into the
host genome inherently harbors the risk of increased
Figure 3 Induced pluripotent stem cell clone spontaneous differentiation into cells of embryonic germ layers. Wilms tumor (WT)-
induced pluripotent stem (iPS) cell, systemic lupus erythematosus (SLE)-iPS cell and autosomal-dominant polycystic kidney disease (ADPKD)-iPS
cell clones were allowed to spontaneously differentiate as embryoid bodies in suspension, followed by adherent culture for 10 to 14 days.
Differentiated cells were immunostained for markers of ectoderm, endoderm and mesoderm lineages b-III-tubulin (green), FOXA2 (red) and
CD31 (PECAM-1) (green), respectively. Nuclei were stained with 4,6-diamidino-2-phenylindole. All images were obtained at 40× magnification.
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In addition, integration of reprogramming vectors could
lead to sustained expression or reactivation of reprogram-
ming factors, including proto-oncogene c-MYC. Expres-
sion of reprogramming factors could prevent proper
differentiation of iPS cells, while reactivation of c-MYC
expression can increase the risk of tumorigencity in vivo
[33]. In our study, we used lentiviral vectors for repro-
gramming, where pluripotency factors were driven by a
retroviral SFFV promoter. Although previous studies have
demonstrated efficient suppression of a retroviral promo-
ter in pluripotent stem cells [14], due to the pluripotency-
associated factor TRIM28 [34], we found sustained trans-
gene-specific transcripts in most of the patient-specific iPS
cell clones tested. This was unexpected as we previously
saw strong suppression of transgene expression in BJ
fibroblast-derived iPS cell clones (data not shown). It is
possible that this discrepancy was due to the difference in
somatic cell sources used for reprogramming (fibroblasts
vs. keratinocytes), or was simply due to clonal variations.
To avoid the issues associated with the use of integrating
vectors, it would be necessary to reprogram patient cells
without using integrating vectors, especially for future
clinical applications. Notably, various reports have demon-
strated the possible cellular reprogramming strategies
without using integrating vectors, including adenoviral
vectors, episomal vectors or introduction of reprogram-
ming proteins, RNAs or miRNAs [35-41]. We have
recently reprogrammed patient’s somatic cells using non-
integrating Sendai viral vectors and generated genomic
Figure 4 Wilms tumor and systemic lupus erythematosus induced pluripotent stem cells form teratoma in immunodeficient mice.
Wilms tumor (WT)-induced pluripotent stem (iPS) cell, systemic lupus erythematosus (SLE)-iPS cell and autosomal-dominant polycystic kidney
disease (ADPKD)-iPS cell clones were injected subcutaneously into SCID-Beige mice. Tumors were detected from the site of injection and
harvested after 3 to 5 months, examined for the presence of cells of three embryonic germ layers. H & E-stained teratoma showed multiple
differentiated tissues including cells of ectoderm, neuronal rosette-like structures (indicated *), endoderm (gut tube-like structures, intestinal
epithelial cells) and mesoderm (adipose-like tissue, muscle-like tissue). Magnification 10×.
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rently in the process of analyzing the differences between
iPS cells made with lentiviral vectors and nonintegrating
Sendai vectors.
iPS cell technology enables the generation of patient-
specific pluripotent stem cells that carry patient/disease-
associated genotypes. Disease-specific iPS cells have been
produced from various diseases including amyotrophic
lateral sclerosis, Parkinson’s disease, type 1 diabetes and
Down’s syndrome [20,21]. These clones provide unique
opportunities to study disease-specific pathogenesis in
vitro and in vivo. For instance, amyotrophic lateral sclero-
sis patient-specific iPS cells were successfully directed to
differentiate into motor neurons, the cell type destroyed
in amyotrophic lateral sclerosis [20]. iPS cells from auto-
somal kidney disease, such as ADPKD, would be useful
for disease modeling, drug discovery and, eventually,
autologous cell replacement therapies. We were the first
to demonstrate successful iPS cell derivation from an
ADPKD patient. As predicted, all ADPKD patient-
derived iPS cells retained the W3842X mutation in the
PKD1 gene. As these cells were not derived from cystic
epithelium, we would not expect them to have further
somatic mutations of PKD1 that may be important for
cyst development. Differentiation of these iPS cells into
collecting duct epithelial cells would allow their charac-
teristics to be compared with wild-type cells.
Although renal transplantation has proven successful
in treating patients with ESRD, the therapy is hampered
by the shortage of donor organs. Differentiation of pluri-
potent stem cells into specific renal cell types, or possi-
bly a transplantable whole kidney, would enable the
potential of cell therapy for ESRD. Due to its complex
structure and function, however, the kidney remains one
of the most challenging organs to reconstruct. Extensive
studies have established a method to efficiently induce
mouse ES cells into renal progenitors and fully differen-
tiated renal cells. For instance, treatment of mouse ES
cells with the combinations of hepatocyte growth factor,
activin A and Wnt4 [42], activin A, BMP-7 and retinoic
acid [43], activin alone [44], or all of the four factors
[45] has been shown to induce formation of intermedi-
ate mesoderm. Notably, derived intermediate mesoderm
formed tubule-like structures in developing mouse kid-
ney [42-44]. Although directed differentiation of human
ES cells into renal lineage expressing lineage-specific
markers has been reported using multiple growth factors
[46,47], renal differentiation of human pluripotent stem
cells needs further evaluation. Once an efficient differen-
tiation protocol is established to differentiate human
pluripotent stem cells into functional renal tissues, auto-
logous iPS cells could bring in a novel, autologous kid-
ney replacement therapy.
Conclusions
Taken together our results demonstrate successful gen-
eration of keratinocyte-derived iPS cells from patients
after kidney transplant maintained on chronic immuno-
suppression. Our results also indicate the feasibility of
renal disease-specific iPS cell derivation from patients
with a single gene mutation, such as ADPKD.
Additional material
Additional file 1: Antibodies and primer sequences. Supplementary
Table 1 presenting primary and secondary antibodies used in this study,
and Supplementary Table 2 presenting primer sequences.
Additional file 2: Supplementary Figure 1 showing patient-specific
iPS cells stained with control antibodies and ADPKD iPS cells
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Figure 5 Sequence analysis confirms PKD1 mutation in
autosomal-dominant polycystic kidney disease-specific induced
pluripotent stem cells. Autosomal-dominant polycystic kidney
disease (ADPKD) patient DNA and ADPKD- induced pluripotent
stem (iPS) cell DNA were analyzed by sequencing analysis.
Sequence of exon 41 of PKD1 showing the 11,525G > A change
resulting in W3842X in the ADPKD-iPS cells (center) and the
patient’s germline DNA (top) but not in the Wilms tumor (WT)-iPS
cells (bottom).
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